Top

Published in:

Open Access 01-12-2020 | Chloroquin | Commentary

Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2

Authors: Nicholas E. Ingraham, David Boulware, Matthew A. Sparks, Timothy Schacker, Bradley Benson, Jeffrey A. Sparks, Thomas Murray, John Connett, Jeffrey G. Chipman, Anthony Charles, Christopher J. Tignanelli

Published in: Critical Care | Issue 1/2020

Excerpt

The 2020 COVID-19 pandemic has stunned the world, financial markets, and healthcare systems. Researchers are rushing to identify effective treatments while maintaining rigorous adherence to the scientific method. Clinicians are doing their best to provide evidence-based care in a setting of very little good evidence. To date, no effective treatments exist for COVID-19 management. Unfortunately, traditional and social media coupled with world leader commentary have led some to believe hydroxychloroquine offers a bona fide cure and even prevention. The purpose of this commentary is to review the medical literature related to hydroxychloroquine building on knowledge over the past 17 years since the 2003 SARS-CoV epidemic. …

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(1):69.CrossRef

Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O'Meara MJ, Guo JZ, Swaney DL, Tummino TA, Hüttenhain R et al: A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. bioRxiv 2020:2020.2003.2022.002386, Pre-Print. https://doi.org/10.1101/2020.03.22.002386.

Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, De Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006;49(9):2845–9.CrossRef

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.CrossRef

Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, Chan PK, Sidwell RW. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother. 2006;17(5):275–84.CrossRef

Chen Jun LIUDLIULLIUPXUQXIALLYH: Preliminary study of hydroxychloroquine sulfate in treating common coronavirus disease (COVID-19) patients in 2019. J Zhejiang Univ (Med Sci) 2020, 49(1).

Gautret P LJ, Parola P, et al.: Hydroxychloroquine and azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020, Pre-Print. https://doi.org/10.1101/2020.03.16.20037135.

Nigeria reports chloroquine poisonings after Trump praised drug. https://www.bloomberg.com/news/articles/2020-03-21/nigeria-reports-chloroquine-poisonings-after-trump-praised-drug. Accessed 22 Mar 2020.

Title: Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2
Authors: Nicholas E. Ingraham
David Boulware
Matthew A. Sparks
Timothy Schacker
Bradley Benson
Jeffrey A. Sparks
Thomas Murray
John Connett
Jeffrey G. Chipman
Anthony Charles
Christopher J. Tignanelli
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Chloroquin
Chloroquin
Severe Acute Respiratory Syndrome Coronavirus
SARS-CoV-2
COVID-19
Hydroxychloroquine
Published in: Critical Care / Issue 1/2020
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-020-02894-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Non-febrile COVID-19 patients were common and often became critically ill: a retrospective multicenter cohort study

Crucial role of temporary airborne infection isolation rooms in an intensive care unit: containing the COVID-19 outbreak in South Korea

Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study

High-frequency oscillatory ventilation for PARDS: awaiting PROSPect

Identification of focal ARDS using PF ratio: a cross-sectional study

Three-step checklist for tracheostomy in critically ill COVID-19 patients